Navigation Links
Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury
Date:11/18/2010

and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers.  These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Global ... to reach USD 24.7 billion by 2022, according ... Inc. Growing prevalence of neurological and musculoskeletal disorders ... over the forecast period. The presence of efficient ... advancement in the technologies coupled with implementation of ...
(Date:8/3/2015)... RADNOR, Pa. , Aug. 3, 2015 ... of laboratory products, services and solutions, announces the redesign of ... its customers. When visiting the new site, ... site with bold colors and vivid images.  Each country site ... , an A to Z product menu; and , ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5VWR's New Website Redesign Provides Improved Functionality for Customers 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
... Reportlinker.com announces that a new market research report ... Colorectal Cancer - France Drug Forecasts and Treatment ... Colorectal Cancer - France ... SummaryGlobalData, the industry analysis specialist, has ...
... West Booth# 19112 -- In anticipation of SupplySide West ... that it has entered into a strategic agreement with Mantrose-Haeuser ... distribution of its HIDROX® products, used in dietary supplement and ... "We are looking at the market for dietary supplements and ...
Cached Medicine Technology:Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 14Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 15CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 2CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 3
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... Princeton, NJ (PRWEB) , ... August 03, 2015 ... ... named a finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs ... by and for B2B brands. BESLER Consulting's campaign for the launch of their ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany ... 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in ... whose mission is to develop technology for the sake of humanity – continues ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Goal of 40 million doses by end of October won,t ... -- Production delays continue to hamper distribution of the H1N1 ... , The vaccine is growing more slowly in egg-based cultures ... this time, Dr. Thomas R. Frieden, director of the U.S. ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... lower-than-normal levels of a naturally-occurring fat hormone may increase ... the blood which claims thousands of lives each year. ... Hospital and the University of Toronto focused on adiponectin, ... organs. The findings were presented this week at the ...
... new Commonwealth Fund report analyzes the similarities, differences, potential ... five committees of jurisdiction in the United States Congress: ... Committees in the Senate and the U.S. House of ... and Commerce committees. The report, Provisions of Comprehensive ...
... research finds that mother,s drug use affects male offspring,s behavior ... monkeys exposed to cocaine in the womb have poor impulse ... research has found. , The male monkeys continued to have ... risk factor for drug abuse, said the researchers, who added ...
... More than half the people who take antidepressants for depression ... depression has been oversimplified and drugs designed to treat it ... the Northwestern University Feinberg School of Medicine. The medications are ... eye instead of the center. A study from ...
Cached Medicine News:Health News:Swine Flu Vaccine Still in Short Supply 2Health News:Swine Flu Vaccine Still in Short Supply 3Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Canadian scientists link fat hormone to death from potentially deadly blood infection 2Health News:Analysis of Congressional health reform bills highlights similarities, differences, costs 2Health News:Cocaine Use in Pregnancy Linked to Impulsivity in Sons 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: